Resmetirom - Madrigal Pharmaceuticals
Alternative Names: MGL-3196; Rezdiffra; VIA-3196Latest Information Update: 08 Oct 2024
At a glance
- Originator Roche
- Developer Madrigal Pharmaceuticals
- Class Antihyperglycaemics; Antihyperlipidaemics; Chlorinated hydrocarbons; Ethers; Hepatoprotectants; Ketones; Nitriles; Pyridazines; Small molecules; Triazines
- Mechanism of Action Thyroid hormone receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-alcoholic steatohepatitis
- Phase II Hyperlipoproteinaemia type IIa
Most Recent Events
- 30 Sep 2024 Efficacy data from a phase-II trial MAESTRO-NASH in Non-alcoholic steatohepatitis released by Madrigal Pharmaceuticals
- 07 Aug 2024 Madrigal Pharmaceuticals intends to directly commercialise Resmetirom in Europe following the EMA's decision, expected in mid-2025
- 09 Apr 2024 Launched for Non-alcoholic steatohepatitis in USA (PO)